14. The Role of Meta-analyses in Clinical Research: Uses and Limitations
LA Stewart - Clinical Trials in Neurology, 2001 - books.google.com
... The Role of Meta-analyses in Clinical Research: Uses and Limitations 161 Box 14.1. ...
A?3.78 8.74 0.65 Trial B?2.64 2.46 034 Trial C?3.48 3.25 0.34 Trial D ...
-

Pharmacologic preservation of the hemostatic system during cardiac surgery -
JH Levy - The Annals of Thoracic Surgery, 2001 - Soc Thorac Surgeons
... 0.55; 95% confidence interval [CI] 0.34 to 0.90 ... heart centers now administer clopidogrel
before anticipated ... Uses of antithrombin III concentrate in congenital ...

Warfarin (Coumadin)
LG Gomella, SA Haist - 2007 - McGraw-Hill's AccessMedicine
... Clonidine, Oral (Catapres). Clonidine, Transdermal (Catapres TTS). Clopidogrel
(Plavix). Clorazepate (Tranxene) [C-IV]. Clotrimazole (Lotrimin, Mycelex) [OTC]. ...

Evaluation of an Absorbable Cyanoacrylate Adhesive as a Suture Line Sealant1 -
PI Ellman, T Brett Reece, TS Maxey, C Tache-Leon, … - Journal of Surgical Research, 2005 - Elsevier
... platelet agents such as the Plavix product becoming ... scores of 0.34, 1.04, and 0.34,
respectively; however ... A new compound that uses polyethylene glycol (Coseal ...

Can Computed Tomographic Angiogram Diagnose Cerebral Vasospasm? Correlation between Vessel …
S Ferguson, DSMD Rosen, D Bardo, RL Macdonald - Neurosurgery, 2006 - neurosurgery-online.com
Page 1. Paper 19 Analysis of Cavernous Malformation Resection Results David
Netuka, MD, Vladimir Benes, MD, Petr Kozler, Ph.D. (Prague ...

Poor Outcomes in Patients with Angiographically Negative Subarachnoid Hemorrhage: Paper 29
YJ Zhang, T Tanaka, OBMD Samuels, CM Cawley, DLMD … - Neurosurgery, 2006 - neurosurgery-online.com
Page 1. Paper 19 Analysis of Cavernous Malformation Resection Results David
Netuka, MD, Vladimir Benes, MD, Petr Kozler, Ph.D. (Prague ...

Clazosentan Attenuated Impairment of Cerebral Perfusion after Aneurysmal Subarachnoid Hemorrhage: …
M Barth, HH Capelle, E M?nch, C Thome, J Woitzik, … - Neurosurgery, 2006 - neurosurgery-online.com
Page 1. Paper 19 Analysis of Cavernous Malformation Resection Results David
Netuka, MD, Vladimir Benes, MD, Petr Kozler, Ph.D. (Prague ...

Subarachnoid Hemorrhage in Patients Aged 80 Years and Older: Clinical Outcome of Patients Managed …
D Roy, F Guilbert, J Raymond, T Nguyen, D Iancu, H … - Neurosurgery, 2006 - neurosurgery-online.com
Page 1. Paper 19 Analysis of Cavernous Malformation Resection Results David
Netuka, MD, Vladimir Benes, MD, Petr Kozler, Ph.D. (Prague ...

[CITATION] Paper 19 Analysis of Cavernous Malformation Resection Results
D Netuka, V Benes, P Kozler

Outcome of Surgical Clipping of 40 Complex Basilar Aneurysms Using the Transcavernous Route: Paper …
AFMD Krisht, K Bikmaz, PA Kadri, S Partington - Neurosurgery, 2006 - neurosurgery-online.com
Page 1. Paper 19 Analysis of Cavernous Malformation Resection Results David
Netuka, MD, Vladimir Benes, MD, Petr Kozler, Ph.D. (Prague ...

THURSDAY, Aug. 17 (HealthDay News) -- The Sanofi Aventis heart drug Plavix (clopidogrel bisulfate) received new approval from the U.S. Food and Drug Administration on Thursday to treat a type of heart attack caused by the sudden blockage of an artery.

About 500,000 Americans annually have this type of severe heart attack, known as an acute ST-segment elevation myocardial infarction (STEMI), the agency said.

Plavix, first approved in 1997 to prevent dangerous blood clots, was granted new approval to prevent subsequent blockage in STEMI patients that could lead to more heart attacks or stroke, the FDA said. The new approval is aimed at patients whose doctors don't recommend an artery-clearing procedure known as angioplasty.

Plavix has been associated with serious side effects including bleeding, low white blood cell counts, and a condition called thrombocytopenic purpura, characterized by low platelet counts and spontaneous bleeding and clotting, the agency said.

More information

To learn more about heart attack, visit Medline Plus.